Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Extensively drug-resistant tuberculosis
Multidrug-resistant tuberculosis
Pre-extensively drug-resistant tuberculosis
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
11
2022
revised:
11
03
2023
accepted:
10
04
2023
medline:
17
5
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
To estimate the pooled proportion of extensively drug-resistant tuberculosis (XDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) in patients with multidrug-resistant TB (MDR-TB). We systematically searched articles from electronic databases: MEDLINE (PubMed), ScienceDirect, and Google Scholar. We also searched gray literature from the different literature sources main outcome of the review was either XDR-TB or pre-XDR-TB in patients with MDR-TB. We used the random-effects model, considering the substantial heterogeneity among studies. Heterogeneity was assessed by subgroup analyses. STATA version 14 was used for analysis. A total of 64 studies that reported on 12,711 patients with MDR-TB from 22 countries were retrieved. The pooled proportion of pre-XDR-TB was 26% (95% confidence interval [CI]: 22-31%), whereas XDR-TB in MDR-TB cases was 9% (95% CI: 7-11%) in patients treated for MDR-TB. The pooled proportion of resistance to fluoroquinolones was 27% (95% CI: 22-33%) and second-line injectable drugs was 11% (95% CI: 9-13%). Whereas the pooled resistance proportions to bedaquiline, clofazimine, delamanid, and linezolid were 5% (95% CI: 1-8%), 4% (95% CI: 0-10%), 5% (95% CI; 2-8%), and 4% (95% CI: 2-10%), respectively. The burden of pre-XDR-TB and XDR-TB in MDR-TB were considerable. The high burdens of pre-XDR-TB and XDR-TB in patients treated for MDR-TB suggests the need to strengthen TB programs and drug resistance surveillance.
Identifiants
pubmed: 37072053
pii: S1201-9712(23)00524-6
doi: 10.1016/j.ijid.2023.04.392
pmc: PMC10302157
mid: NIHMS1910341
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Fluoroquinolones
0
Clofazimine
D959AE5USF
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-63Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests The authors have no competing interests to declare.
Références
Clin Infect Dis. 2008 Aug 15;47(4):450-7
pubmed: 18616396
J Clin Microbiol. 2012 Jul;50(7):2404-13
pubmed: 22553245
Afr Health Sci. 2021 Sep;21(3):968-974
pubmed: 35222556
Clin Infect Dis. 2008 Oct 1;47(7):e57-63
pubmed: 18715157
Psychol Methods. 2006 Jun;11(2):193-206
pubmed: 16784338
Korean J Intern Med. 2015 May;30(3):325-34
pubmed: 25995663
Clin Respir J. 2011 Jan;5(1):19-25
pubmed: 21159137
Int J Tuberc Lung Dis. 2010 Oct;14(10):1259-65
pubmed: 20843416
J Infect. 2021 Mar;82(3):371-377
pubmed: 33556430
PLoS One. 2021 Jan 28;16(1):e0245687
pubmed: 33507946
Tuberculosis (Edinb). 2013 Jan;93(1):84-8
pubmed: 23146281
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1112-1117
pubmed: 28911354
J Korean Med Sci. 2017 Apr;32(4):636-641
pubmed: 28244290
BMC Infect Dis. 2013 Jul 12;13:315
pubmed: 23849244
Eur J Microbiol Immunol (Bp). 2022 Apr 14;:
pubmed: 35420996
J Infect Chemother. 2017 Dec;23(12):820-825
pubmed: 29066216
J Glob Antimicrob Resist. 2017 Dec;11:75-80
pubmed: 28743645
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Eur Respir J. 2021 Jun 4;57(6):
pubmed: 33243847
Clin Microbiol Infect. 2018 Aug;24(8):889-895
pubmed: 29175351
BMC Infect Dis. 2021 Apr 8;21(1):330
pubmed: 33832459
Mem Inst Oswaldo Cruz. 2020;115:e200055
pubmed: 32401997
Indian J Med Res. 2009 Oct;130(4):392-5
pubmed: 19942741
PLoS One. 2015 Jan 21;10(1):e0116798
pubmed: 25606853
PLoS One. 2012;7(2):e32103
pubmed: 22384153
BMC Med Res Methodol. 2014 Apr 01;14:45
pubmed: 24690082
PLoS One. 2020 Feb 13;15(2):e0229040
pubmed: 32053661
Int J Tuberc Lung Dis. 2017 Mar 1;21(3):303-308
pubmed: 28225340
BMC Infect Dis. 2016 Aug 17;16:423
pubmed: 27534745
Pneumonol Alergol Pol. 2011;79(4):278-87
pubmed: 21678278
J Glob Antimicrob Resist. 2021 Mar;24:6-13
pubmed: 33279682
Indian J Med Res. 2016 Mar;143(3):341-7
pubmed: 27241648
J Epidemiol Glob Health. 2020 Mar;10(1):42-45
pubmed: 32175709
Emerg Infect Dis. 2010 Feb;16(2):264-71
pubmed: 20113557
Infect Genet Evol. 2020 Mar;78:104127
pubmed: 31783187
Rev Inst Med Trop Sao Paulo. 2021 Mar 24;63:e19
pubmed: 33787739
Public Health. 2020 Mar;180:17-21
pubmed: 31837610
Ann Lab Med. 2018 Nov;38(6):563-568
pubmed: 30027700
Eur Spine J. 2013 Jun;22 Suppl 4:647-52
pubmed: 22270244
Biomed Res Int. 2021 Nov 19;2021:8817442
pubmed: 34840984
Ann Clin Microbiol Antimicrob. 2021 Dec 17;20(1):84
pubmed: 34920727
Antimicrob Resist Infect Control. 2021 Aug 26;10(1):126
pubmed: 34446095
J Microbiol Immunol Infect. 2018 Feb;51(1):88-93
pubmed: 28698044
BMJ Open. 2021 Apr 15;11(4):e044096
pubmed: 33858870
PLoS One. 2020 Dec 7;15(12):e0243493
pubmed: 33284842
BMC Infect Dis. 2017 Apr 24;17(1):300
pubmed: 28438132
Braz J Infect Dis. 2021 Jan-Feb;25(1):101544
pubmed: 33592172
Int J Mycobacteriol. 2012 Sep;1(3):131-6
pubmed: 26787208
Tuberculosis (Edinb). 2012 Sep;92(5):404-6
pubmed: 22789499
J Infect Chemother. 2013 Apr;19(2):243-8
pubmed: 23053506
Tuberc Respir Dis (Seoul). 2012 Jul;73(1):48-55
pubmed: 23101024
Int J Tuberc Lung Dis. 2009 Sep;13(9):1148-53
pubmed: 19723406
PLoS Med. 2013;10(4):e1001419
pubmed: 23585737
Infect Drug Resist. 2021 May 04;14:1679-1689
pubmed: 33976556
Western Pac Surveill Response J. 2016 Jun 08;7(2):35-40
pubmed: 27508089
J Pak Med Assoc. 2021 Mar;71(3):912-915
pubmed: 34057947
Annu Rev Med. 2009;60:307-20
pubmed: 19630575
Infect Drug Resist. 2017 Jun 10;10:167-174
pubmed: 28706448
Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60
pubmed: 19723407
Trans R Soc Trop Med Hyg. 2019 Feb 1;113(2):56-64
pubmed: 30517697
Tuberculosis (Edinb). 2014 May;94(3):277-81
pubmed: 24751554
Infect Drug Resist. 2021 Mar 17;14:1089-1104
pubmed: 33762833
Medicine (Baltimore). 2020 Oct 23;99(43):e22608
pubmed: 33120748
PLoS One. 2015 Feb 17;10(2):e0117361
pubmed: 25689373
J Glob Antimicrob Resist. 2021 Sep;26:241-248
pubmed: 34214699